Patents by Inventor Wesley Wehsin Han
Wesley Wehsin Han has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9694021Abstract: The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements and/or similar preservative standards (e.g., EP and JP).Type: GrantFiled: November 20, 2013Date of Patent: July 4, 2017Assignee: ALCON RESEARCH, LTDInventors: Masood A. Chowhan, Wesley Wehsin Han, L. Wayne Schneider
-
Publication number: 20160361254Abstract: The present invention is directed to the provision of an ophthalmic composition suitable for intravitreal injection. The composition includes an amount of complexing agent that reacts with one or more endogenous components (e.g., hyaluronic acid) in the eye to form a mass of enhanced viscosity. This mass can aid in creating a desirable release profile of therapeutic agent.Type: ApplicationFiled: August 24, 2016Publication date: December 15, 2016Inventors: Masood A. Chowhan, Thomas C. Hohman, Ernesto J. Castillo, Wesley Wehsin Han
-
Patent number: 9446093Abstract: The present invention is directed to the provision of an ophthalmic composition suitable for intravitreal injection. The composition includes an amount of complexing agent that reacts with one or more endogenous components (e.g., hyaluronic acid) in the eye to form a mass of enhanced viscosity. This mass can aid in creating a desirable release profile of therapeutic agent.Type: GrantFiled: October 18, 2013Date of Patent: September 20, 2016Assignee: Alcon Research, Ltd.Inventors: Masood A. Chowhan, Thomas C. Hohman, Ernesto J. Castillo, Wesley Wehsin Han
-
Patent number: 8921337Abstract: The present invention generally relates to suspension compositions having a carboxyvinyl polymer such as a carbomer, a galactomannan such as guar, and a borate compound. A sparingly soluble particulate compound such as nepafenac is also included in the compositions. The sparingly soluble particulate compound has a small particle size to enhance bioavailability of the compound.Type: GrantFiled: December 1, 2010Date of Patent: December 30, 2014Assignee: Alcon Research, Ltd.Inventors: Masood A. Chowhan, Malay Ghosh, Bahram Asgharian, Wesley Wehsin Han
-
Publication number: 20140107121Abstract: The invention provides solution compositions comprising olopatadine and a PDE4 inhibitor compound of Formula I: The invention also provides methods for treating allergic and inflammatory diseases. More particularly, the present invention relates to formulations of olopatadine and their use for treating and/or preventing allergic or inflammatory disorders of the eye, nose, skin, and ear.Type: ApplicationFiled: December 17, 2013Publication date: April 17, 2014Applicant: Alcon Research, Ltd.Inventors: L. Wayne Schneider, Wesley Wehsin Han, Masood A. Chowhan
-
Publication number: 20140094419Abstract: The present invention is directed to the provision of an ophthalmic composition suitable for intravitreal injection. The composition includes an amount of complexing agent that reacts with one or more endogenous components (e.g., hyaluronic acid) in the eye to form a mass of enhanced viscosity. This mass can aid in creating a desirable release profile of therapeutic agent.Type: ApplicationFiled: October 18, 2013Publication date: April 3, 2014Applicant: Alcon Research Ltd.Inventors: Masood A. Chowhan, Thomas C. Hohman, Ernesto J. Castillo, Wesley Wehsin Han
-
Publication number: 20140080793Abstract: The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements and/or similar preservative standards (e.g., EP and JP).Type: ApplicationFiled: November 20, 2013Publication date: March 20, 2014Applicant: Alcon Research, Ltd.Inventors: Masood A. Chowhan, Wesley Wehsin Han, L. Wayne Schneider
-
Patent number: 8399508Abstract: Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.Type: GrantFiled: June 30, 2011Date of Patent: March 19, 2013Assignee: Alcon Pharmaceuticals Ltd.Inventors: Onkar N. Singh, G. Michael Wall, Rajni Jani, Masood A. Chowhan, Wesley Wehsin Han
-
Patent number: 8323630Abstract: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borate or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred.Type: GrantFiled: April 14, 2011Date of Patent: December 4, 2012Assignee: Alcon Research, Ltd.Inventors: Bhagwati P. Kabra, Masood A. Chowhan, L. Wayne Schneider, Wesley Wehsin Han
-
Patent number: 8268299Abstract: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borat or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred.Type: GrantFiled: September 20, 2007Date of Patent: September 18, 2012Assignee: Alcon Research, Ltd.Inventors: Bhagwati P. Kabra, Masood A. Chowhan, L. Wayne Schneider, Wesley Wehsin Han
-
Publication number: 20120053161Abstract: Solution formulations containing a corticosteroid, cyclodextrin, and xanthan gum are disclosed. The formulations are intended for topical application to the eye, ear, or nose.Type: ApplicationFiled: July 28, 2009Publication date: March 1, 2012Applicant: Novartis AGInventors: Ernesto J. Castillo, Huixiang Zhang, Glenn D. Stafford, Wesley Wehsin Han
-
Publication number: 20120022149Abstract: There are disclosed pharmaceutical compositions, particularly ophthalmic compositions, that contain relatively high concentrations of solubility enhancing polymer (e.g., polyether polymer, polyvinyl polymer or a combination thereof) for providing enhanced solubility of one or more therapeutic agents. In a preferred embodiment, the composition is a multi-dose topical aqueous ophthalmic composition that contains relatively high concentrations of solubility enhancing polymer (e.g., polyether polymer, polyvinyl polymer or a combination thereof) for providing enhanced solubility of one or more therapeutic agents.Type: ApplicationFiled: July 20, 2011Publication date: January 26, 2012Inventors: Masood A. Chowhan, Malay Ghosh, Wesley Wehsin Han, Way-Yu Lin, Vincent Nguyen
-
Publication number: 20110306659Abstract: Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.Type: ApplicationFiled: June 30, 2011Publication date: December 15, 2011Applicant: Novartis AGInventors: Onkar N. Singh, G. Michael Wall, Rajni Jani, Masood A. Chowhan, Wesley Wehsin Han
-
Publication number: 20110269719Abstract: The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements and/or similar preservative standards (e.g., EP and JP).Type: ApplicationFiled: April 26, 2011Publication date: November 3, 2011Inventors: Masood A. Chowhan, Wesley Wehsin Han, L. Wayne Schneider
-
Publication number: 20110195132Abstract: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borate or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred.Type: ApplicationFiled: April 14, 2011Publication date: August 11, 2011Applicant: ALCON RESEARCH, LTD.Inventors: Bhagwati P. Kabra, Masood A. Chowhan, L. Wayne Schneider, Wesley Wehsin Han
-
Patent number: 7977376Abstract: Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.Type: GrantFiled: February 7, 2007Date of Patent: July 12, 2011Assignee: Novartis AGInventors: Onkar N. Singh, G. Michael Wall, Rajni Jani, Masood A. Chowhan, Wesley Wehsin Han
-
Publication number: 20110135743Abstract: The present invention generally relates to suspension compositions having a carboxyvinyl polymer such as a carbomer, a galactomannan such as guar, and a borate compound. A sparingly soluble particulate compound such as nepafenac is also included in the compositions. The sparingly soluble particulate compound has a small particle size to enhance bioavailability of the compound.Type: ApplicationFiled: December 1, 2010Publication date: June 9, 2011Applicant: ALCON RESEARCH, LTD.Inventors: Masood A. Chowhan, Malay Ghosh, Bahram Asgharian, Wesley Wehsin Han
-
Publication number: 20110124734Abstract: The present invention relates to methods for disinfecting or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid and a phase transfer agent for a time sufficient to disinfect or clean the lens. This specification further discloses a formulation for disinfecting a contact lens comprising an N-halogenated amino acid and a phase transfer agent.Type: ApplicationFiled: January 31, 2011Publication date: May 26, 2011Applicant: ALCON RESEARCH, LTD.Inventors: Masood A. Chowhan, Wesley Wehsin Han, L. Wayne Schneider, David W. Stroman, Nissanke L. Dassanayake
-
Publication number: 20110082145Abstract: The invention provides solution compositions comprising olopatadine and a PDE4 inhibitor compound of Formula I: The invention also provides methods for treating allergic and inflammatory diseases. More particularly, the present invention relates to formulations of olopatadine and their use for treating and/or preventing allergic or inflammatory disorders of the eye, nose, skin, and ear.Type: ApplicationFiled: October 1, 2010Publication date: April 7, 2011Applicant: ALCON RESEARCH, LTD.Inventors: L. Wayne Schneider, Wesley Wehsin Han, Masood A. Chowhan
-
Publication number: 20110071116Abstract: The present invention relates to a formulation comprising a N-halogenated amino acid and a phase transfer agent. The present invention also describes a method for disinfecting and/or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid salt for a time sufficient to disinfect and/or clean the lens.Type: ApplicationFiled: November 24, 2010Publication date: March 24, 2011Applicant: ALCON RESEARCH, LTD.Inventors: L. Wayne Schneider, Wesley Wehsin Han, Masood A. Chowhan, David W. Stroman, W. Dennis Dean, Michael S. Gaines